InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

- Current share price for TLX : $16.160

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,491 Investor Briefing - Asia Strategy 3 Nov 2020 8:21AM $2.160 $16.160 risen by 648.15%
$5,491 Investor Call - Strategic Licence and Commercial Partnership 2 Nov 2020 2:21PM $1.675 $16.160 risen by 864.78%
$5,491 Appendix 3B - Proposed Issue of Securities 2 Nov 2020 2:20PM $1.675 $16.160 risen by 864.78%
$5,491 Strategic Licence and Partnership for Greater China Market 2 Nov 2020 2:20PM $1.675 $16.160 risen by 864.78%
$5,491 Trading Halt 30 Oct 2020 8:24AM $1.675 $16.160 risen by 864.78%
$5,491 App 4C and Activities Report for September 2020 Quarter 30 Oct 2020 8:23AM $1.675 $16.160 risen by 864.78%
$5,491 Licence Agmt with DKFZ for Image-Guided Prostate Surgery 28 Oct 2020 8:22AM $1.645 $16.160 risen by 882.37%
$5,491 Completion of PhI Enrolment of Japanese Renal Cancer Study 27 Oct 2020 8:18AM $1.695 $16.160 risen by 853.39%
$5,491 Appendix 3G - issue of Rights under Equity Incentive Plan 13 Oct 2020 8:05AM $1.800 $16.160 risen by 797.78%
$5,491 FDA grants Orphan Drug Designation for glioma imaging agent 6 Oct 2020 8:21AM $1.645 $16.160 risen by 882.37%
$5,491 Telix submits NDA to US FDA for Prostate Cancer Imaging 24 Sep 2020 8:24AM $1.760 $16.160 risen by 818.18%
$5,491 First patients dosed in Phase I study of APOMAB theranostic 21 Sep 2020 8:23AM $1.800 $16.160 risen by 797.78%
$5,491 Strategic Collaboration with Varian for Prostate Imaging 3 Sep 2020 8:21AM $1.710 $16.160 risen by 845.03%
$5,491 IRE Distribution Partnership for Prostate Cancer Imaging 1 Sep 2020 8:09AM $1.650 $16.160 risen by 879.39%
$5,491 FDA grants orphan drug designation for TLX102 31 Aug 2020 8:10AM $1.610 $16.160 risen by 903.73%
$5,491 Half Year Shareholder Update 21 Aug 2020 7:32AM $1.430 $16.160 risen by 1,030.07%
$5,491 Report for half-year to 30 June 2020 20 Aug 2020 5:16PM $1.430 $16.160 risen by 1,030.07%
$5,491 First patient dosed in renal cancer imaging study in Japan 18 Aug 2020 8:14AM $1.350 $16.160 risen by 1,097.04%
$5,491 Drug Master File for Glioblastoma Product Filed with FDA 11 Aug 2020 8:16AM $1.365 $16.160 risen by 1,083.88%
$5,491 Investor call - H1 Results and Company Update 11 Aug 2020 8:15AM $1.365 $16.160 risen by 1,083.88%
$5,491 Appendix 4C and Activities Report - June 2020 quarter 27 Jul 2020 8:22AM $1.300 $16.160 risen by 1,143.08%
$5,491 Receipt of $11.4M R&D tax rebate 21 Jul 2020 10:08AM $1.315 $16.160 risen by 1,128.90%
$5,491 App 2A - issue of shares following exercise of options 15 Jul 2020 8:20AM $1.390 $16.160 risen by 1,062.59%
$5,491 Strategic collaboration with RefleXion for high-risk cancers 8 Jul 2020 8:23AM $1.530 $16.160 risen by 956.21%
$5,491 FDA feedback on Prostate Cancer Therapy Phase 3 Trial Design 8 Jul 2020 8:22AM $1.530 $16.160 risen by 956.21%

701 - 725 of 951 results

Page 29 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.